- Investor's Business Daily•14 hours ago
Potential blockbuster combo drugs from Sanofi and Novo Nordisk are near launch, and reducing death rates may be next battleground.
- Forbes•18 hours ago
Is this the best time in a long time to be buying biotech stocks now that their lagging performance has made them relatively undervalued to other sectors? Todd Hagopian is buying because he believes the biotech industry is ripe for acquisitions as large, cash-flow rich drug companies look for promising new products. This is the 2nd in a three-part series focusing on potential mergers and acquisitions in the biotech sector.
After hours: 42.15-0.16 (-0.38%) as of 5:16 PM EDT
|Bid||42.28 x 1900|
|Ask||42.29 x 600|
|52wk Range||37.41 - 54.98|
|Day's Range||41.98 - 42.45|
|Avg Vol (3m)||2,321,230|
As of 4:02 PM EDT. Market closed.